Immune-mediated processes in neurodegeneration: where do we stand?

被引:0
|
作者
Marc Fakhoury
机构
[1] Université de Montréal,Department of Neurosciences, Faculty of Medicine
来源
Journal of Neurology | 2016年 / 263卷
关键词
Immune response; Inflammation; Microglia; Neurodegenerative diseases; T cells;
D O I
暂无
中图分类号
学科分类号
摘要
Neurodegeneration is a pathological condition that predominantly affects neurons. It represents a large spectrum of disorders with heterogeneous symptoms and distinct clinical features. In addition to the devastating effects it can have on the affected individual, it constitutes a heavy burden to the society in terms of health care costs. Although the exact cause of neurodegeneration is not known, there are plenty of evidences supporting the notion that the immune system is strongly associated with various forms of neurodegenerative diseases. Given the numerous functions of immune cells, a change in their expression can either be beneficial or deleterious to the host. A better understanding of the molecular and cellular processes in neurodegeneration is therefore needed. This could facilitate the development of new therapeutic targets and provide effective means to dampen the progression of neurodegenerative disorders. The overarching aim of this paper is to provide an overview of the roles that the innate and adaptive immune systems play in the central nervous system, and to discuss their beneficial or detrimental effects during neurodegeneration. This paper also critically examines the contribution of immune and inflammatory-mediated responses in the development of neurodegenerative diseases including Alzheimer’s disease (AD), Parkinson’s disease (PD), multiple sclerosis (MS), and amyloid lateral sclerosis by illustrating key findings from animal and human studies.
引用
收藏
页码:1683 / 1701
页数:18
相关论文
共 50 条
  • [21] Investigative dermatology: where do we stand and where do we go?
    Maurer, M.
    von Stebut, E.
    EXPERIMENTAL DERMATOLOGY, 2010, 19 (10) : 857 - 857
  • [22] Rye and health - Where do we stand and where do we go?
    Jonsson, Karin
    Andersson, Roger
    Knudsen, Knud Erik Bach
    Hallmans, Goran
    Hanhineva, Kati
    Katina, Kati
    Kolehmainen, Marjukka
    Kyro, Cecilie
    Langton, Maud
    Nordlund, Emilia
    Laerke, Helle Nygaard
    Olsen, Anja
    Poutanen, Kajsa
    Tjonneland, Anne
    Landberg, Rikard
    TRENDS IN FOOD SCIENCE & TECHNOLOGY, 2018, 79 : 78 - 87
  • [23] Where do we stand in the OECD?
    Buske, L
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 1997, 156 (03) : 464 - 464
  • [24] Where do we stand with hepatoblastoma?
    Schnater, JM
    Köhler, SE
    Lamers, WH
    von Schweinitz, D
    Aronson, DC
    CANCER, 2003, 98 (04) : 668 - 678
  • [25] Inflation: Where do we stand?
    Martin, J
    INTERNATIONAL JOURNAL OF MODERN PHYSICS A, 2005, 20 (19): : 4676 - 4682
  • [26] GFIS - Where do we stand?
    Anon
    IUFRO News, 2002, 31 (02):
  • [27] The GSEs: Where do we stand?
    Poole, William
    FEDERAL RESERVE BANK OF ST LOUIS REVIEW, 2007, 89 (03): : 143 - 151
  • [28] VITILIGO - WHERE DO WE STAND
    ORTONNE, JP
    BOSE, SK
    PIGMENT CELL RESEARCH, 1993, 6 (02): : 61 - 72
  • [29] Where do we stand on econophysics?
    Carbone, A.
    Kaniadakis, G.
    Scarfone, A. M.
    PHYSICA A-STATISTICAL MECHANICS AND ITS APPLICATIONS, 2007, 382 (01) : XI - XIV
  • [30] WHERE DO WE STAND WITH PPIS
    WELSH, JS
    AMERICAN PHARMACY, 1979, 19 (12): : 12 - 14